RxDoctor Payments Data

Rishabh Gulati, MD

Gastroenterology · Silverdale, WANPI 1649688698

Payments from drug & device makers

$4,530in general payments, 2019–2025

Across 94 payments — averaging $48.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • AbbVie$636
  • Sanofi$269
  • Takeda Pharmaceuticals U.S.A., Inc.$222
  • Phathom Pharmaceuticals, Inc.$168
  • Madrigal Pharmaceuticals$134
  • plus $856 from 17 others

What the payments were for

  • Consulting fees$1,65036%
  • Travel & lodging$982%
  • Food & beverage$2,78361%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,530 in reported general payments places this provider in the 75th percentile of 447 gastroenterology providers in Washington.

See all gastroenterology providers in Washington

Medicare billing

Part B allowed, 2024
$190,587
Medicare patients
577
Services billed
2,454

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RinvoqUpadacitinib13$120,294
HumiraAdalimumab13$104,753
CreonLipase/Protease/Amylase13$63,437
LinzessLinaclotide16$18,508
Omeprazole253$3,618
Budesonide DrBudesonide15$1,807
Famotidine83$1,738
Pantoprazole Sodium96$1,338
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl45$903
Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl52$817
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl39$545
Dicyclomine Hcl25$361
Peg 3350-ElectrolyteSodium Chloride/Nahco3/Kcl/Peg16$316

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq, Humira, Creon, Linzess$636$306,99255 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 447 gastroenterology providers in Washington.

Other gastroenterology in Silverdale

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →